Abstract:1377 Objectives Small interfering RNA (siRNA) tumor imaging and therapies administered by intravenous injection require a highly efficient delivery system to perform the function of gene silencing. The overall purpose of this study was to develop and characterize a novel integrin αvβ3-specific delivery vector for improving transfection of siRNA in malignant tumors in vitro. Methods For specific siRNA delivery to tumor cells, we adopted a cyclic Arg-Gly-Asp (RGD) peptide as a promising molecule for recognition of tumor tissues expressing integrin ανβ3. To enable siRNA binding, a chimaeric peptide was synthesized by adding nonamer arginine residues (9R) at the carboxy terminus of cyclic-RGD dimer, designated as c(RGD)2-9R. To verify the combination of c(RGD)2-9R with siRNA, electrophoresis on 2% agarose gels was performed. The stability of c(RGD)2-9R/siRNA in different conditions were confirmed by electrophoresis. The efficiency of c(RGD)2-9R peptides transferring siRNA was evaluated in vitro by the methods of flow cytometry and confocal microscopy. All data were analyzed with the statistical software SPSS17.0, and a value of P less than 0.05 was considered to be statistically significant. Results The peptide of c(RGD)2-9R was able to bind siRNA in a dose-dependent manner. An optimal 10:1 molar ratio of c(RGD)2-9R to siRNA was confirmed. The complex of c(RGD)2-9R/siRNA remained stable and complete at room temperature and in fresh 37oC human serum, even after 72h. The results of flow cytometry showed that the average siRNA transfection efficiencies of c(RGD)2-9R and liposome were 61.0%±13.4% and 91.5%±1.84%, respectively, which were all much higher than that of FAM-siRNA alone (8.08%±6.45%) (P Conclusions The chimaeric peptide of c(RGD)2-9R is considered to be an effective siRNA delivery vector in vitro, and a hopeful application in vivo needs further examination.

Construction and Identification of CD147 Sirna Expression Vector

Construction and Identification of Lentiviral Vector-mediated RNA Interference of Epidermal Growth Factor Receptor

[Construction of Shrna Expression Vector Silencing Kir6.2 Gene and to Study Its Influence on the Proliferation and Invasion of HepG2 Cells].

Construction of a lentiviral RNA interference system targeting heparanase based on miR30 and its silencing effect]

Construction and Identification of an Antisense Glucose Transporter-1 Plasmid

Construction and Identification of Sirna Expression Vector Targeting Human BRMS1

Construction and identification of vector against Kir6.2 gene expression in hepatoma cells by short interfering RNAs

Construction of pcDNA3-Endo eukaryon expression plasmid and angiogenesis inhibition in vitro

Construction of heparanase gene-targeted small interfering RNA and its gene silencing effect]

Construction and Identification of the Recombinant Plasmid of Inhibition of Tumor Cell Cortical Actin Assembly Function

Construction and identification of siRNA against tumor necrosis factor receptor associated factor 6 (TRAF6)

The Construction and Characterization of a Novel Adenovirus Vector of Artificial Microrna Targeting EGFR.

Construction of Survivin Sirna Expression Vector and Its Expression in Esophagus Carcinoma Cell Line EC109

Construction of Human Tissue Factor RNA Interference Eukaryotic Expression Vector

Construction of Psuper-H1 RNAi System Inhibiting the Expression of VEGF

Cloning of SARS-CoV-S Gene and Construction of Its Short Interfering RNAs Expression Vector

Construction and Characterization of Crgd-Modified 9-Arginine Peptide As A Novel Vector for Targeted Sirna Delivery

Construction and Application of an Artificial Microrna Expression Vector for Inhibiting PAR4

Construction and Identification of siRNA Expression Vector Targeting Nucleocapsid Protein N gene of PRRSV

Construction and Identification of miR-16 Expression Vector

The Inhibitory Effect of CD 147-Shrna on Expression of CD 147 of Gastric Cell Line SGC7901